Search

Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Journey to better understanding of LGMD: Q&A on the early findings of a new natural history study
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (ESSENCE)
EU-U.S., SWISS-U.S. AND UK EXTENSION TO THE EU-U.S. DATA PRIVACY FRAMEWORK PRIVACY POLICY
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments